VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.
View in:
PubMed
subject areas
Adolescent
Adult
Aged
Allografts
Disease-Free Survival
Female
Graft vs Host Disease
Humans
Incidence
Lymphoma
Male
Melphalan
Middle Aged
Retrospective Studies
Stem Cell Transplantation
Survival Rate
Tissue Donors
Vidarabine
authors with profiles
ISSA F KHOURI
RICHARD E CHAMPLIN
PARTOW KEBRIAEI
FREDRICK B HAGEMEISTER
LUIS E FAYAD
PAOLO ANDERLINI
GABRIELA RONDON
UDAY R POPAT
RIMA M SALIBA
CHITRA HOSING
ELIZABETH SHPALL
MUZAFFAR H QAZILBASH
SIMRIT PARMAR
AMIN MAJID ALOUSI
YAGO NIETO
JASON ROBERT WESTIN
STEFAN OCTAVIAN CIUREA
NATHAN FOWLER
AMANDA L OLSON
QAISER BASHIR
ROHTESH S MEHTA
BETUL ORAN